What is RevMedx?
RevMedx is at the forefront of developing innovative hemorrhage control solutions designed to save lives in critical situations. Their flagship XSTAT devices are engineered for both combat medics and civilian first responders, offering an advanced method for treating life-threatening bleeding. The efficacy and reliability of RevMedx's offerings are recognized by U.S. Special Operations Forces, and they are a recommended solution by the Committee on Tactical Combat Casualty Care. The company provides a range of prescription and over-the-counter products to address the diverse needs of medical professionals and emergency personnel.
How much funding has RevMedx raised?
RevMedx has raised a total of $3.7M across 2 funding rounds:
Series A
$3.5M
Debt
$150K
Series A (2016): $3.5M, investors not publicly disclosed
Debt (2020): $150K led by PPP
Key Investors in RevMedx
PPP
Public-Private Partnership
What's next for RevMedx?
The recent major strategic investment signals a pivotal moment for RevMedx, likely enabling the company to scale its operations, expand its product reach, and further innovate in the life-saving medical device sector. This capital infusion is expected to accelerate the adoption of their hemorrhage control technologies across military and civilian emergency response frameworks, solidifying their position as a key player in pre-hospital trauma care. Future growth may involve broader market penetration and the development of next-generation solutions.
See full RevMedx company page
